NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Is Up 8.8% After Raising 2025 Guidance on Strong Q3 Results – Has The Bull Case Changed?
Ligand Pharmaceuticals reported third quarter 2025 results on November 6, showing a large year-over-year increase in revenue to US$115.46 million and net income of US$117.27 million, along with improved earnings per share figures.
An unusually strong quarterly performance was paired with a raised full-year 2025 guidance, highlighting increased expectations across all core revenue segments, including royalties and product sales.
We'll explore how Ligand Pharmaceuticals' upward revision to...